[go: up one dir, main page]

GT201100318A - Inyección de diacetato de ipamorelin y soluciones de la infusión - Google Patents

Inyección de diacetato de ipamorelin y soluciones de la infusión

Info

Publication number
GT201100318A
GT201100318A GT201100318A GT201100318A GT201100318A GT 201100318 A GT201100318 A GT 201100318A GT 201100318 A GT201100318 A GT 201100318A GT 201100318 A GT201100318 A GT 201100318A GT 201100318 A GT201100318 A GT 201100318A
Authority
GT
Guatemala
Prior art keywords
injection
infusion solutions
ipamorelin
ipamorelin diacetate
diacetate
Prior art date
Application number
GT201100318A
Other languages
English (en)
Inventor
Garcia Rubio Silvina
Beidler Daniel
Weibel Helle
Braglia Riccardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201100318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201100318A publication Critical patent/GT201100318A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE UBICA EN EL CAMPO DE LA QUÍMICA DEL IPAMORELIN Y SE RELACIONA PARTICULARMENTE CON LOS MÉTODOS DE SOLUBILIZACIÓN DEL IPAMORELIN COMO LA SAL DE DIACETATO, PREFERIBLEMENTE EN PRESENCIA DEL EXCESO DE RESIDUOS ÁCIDOS PARA LA ESTABILIDAD Y LA SOLUBILIDAD ÓPTIMAS EN SOLUCIONES DE LA INYECCIÓN Y DE LA INFUSIÓN
GT201100318A 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión GT201100318A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659509P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
GT201100318A true GT201100318A (es) 2014-10-13

Family

ID=42272260

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201100318A GT201100318A (es) 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión

Country Status (24)

Country Link
US (1) US20100317581A1 (es)
EP (1) EP2440180B1 (es)
JP (1) JP2012529510A (es)
KR (1) KR20120030530A (es)
CN (1) CN102481251A (es)
AU (1) AU2010259102B2 (es)
BR (1) BRPI1012931A2 (es)
CA (1) CA2765233A1 (es)
CL (1) CL2011003131A1 (es)
CO (1) CO6470880A2 (es)
CR (1) CR20110618A (es)
CU (1) CU20110232A7 (es)
DO (1) DOP2011000383A (es)
EA (1) EA201270011A1 (es)
EC (1) ECSP11011516A (es)
GT (1) GT201100318A (es)
MX (1) MX2011013113A (es)
NI (1) NI201100212A (es)
NZ (1) NZ596641A (es)
PE (1) PE20121064A1 (es)
SG (1) SG176717A1 (es)
TW (1) TW201106961A (es)
UA (1) UA104762C2 (es)
WO (1) WO2010144265A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6193017B2 (ja) * 2013-06-28 2017-09-06 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
WO2015145860A1 (ja) 2014-03-28 2015-10-01 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115635B1 (ro) * 1993-12-23 2000-04-28 Novo Nordisk As Peptida cu proprietati de eliberare a hormonului de crestere si compozitie farmaceutica cu aceasta
AU4911500A (en) * 1999-06-04 2000-12-28 Novo Nordisk A/S Compositions for the treatment of the catabolic state of prolonged critical illness
JP4874989B2 (ja) * 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
EP2129401B8 (en) * 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
AU2008341160A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну

Also Published As

Publication number Publication date
EP2440180A2 (en) 2012-04-18
AU2010259102B2 (en) 2013-09-12
NI201100212A (es) 2012-04-11
CN102481251A (zh) 2012-05-30
US20100317581A1 (en) 2010-12-16
KR20120030530A (ko) 2012-03-28
CU20110232A7 (es) 2012-06-21
CA2765233A1 (en) 2010-12-16
NZ596641A (en) 2013-12-20
EP2440180B1 (en) 2014-08-27
JP2012529510A (ja) 2012-11-22
SG176717A1 (en) 2012-01-30
TW201106961A (en) 2011-03-01
PE20121064A1 (es) 2012-09-03
MX2011013113A (es) 2012-02-21
AU2010259102A1 (en) 2012-01-12
UA104762C2 (ru) 2014-03-11
CO6470880A2 (es) 2012-06-29
EA201270011A1 (ru) 2012-05-30
CL2011003131A1 (es) 2012-08-17
DOP2011000383A (es) 2012-05-31
WO2010144265A2 (en) 2010-12-16
ECSP11011516A (es) 2012-03-30
WO2010144265A3 (en) 2011-11-24
BRPI1012931A2 (pt) 2018-01-30
CR20110618A (es) 2012-03-02

Similar Documents

Publication Publication Date Title
ECSP13013074A (es) Nuevos derivados de piridina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
GT201400300A (es) Jeringa
GT201300215A (es) Inhibidores de glucosilceramida sintasa
CR20150204A (es) Nuevos derivados de piridina
CR20150250A (es) Nuevos derivados de piridina
BR112013023241A2 (pt) melhorias para entidades biológicas imobilizadas
EA033811B1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
UY34105A (es) Formulación líquida estable de etanercept
CR20150447A (es) Nuevos derivados de pirazol
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
EA201591567A1 (ru) Новые производные пиридина
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.
CR20150511A (es) Nuevos derivados de purina
BR112014010047A2 (pt) novos derivados de pirazina